Pacira BioSciences, Inc. (PCRX)Healthcare | Drug Manufacturers - Specialty & Generic | Brisbane, United States | NasdaqGS
36.34 USD
+0.00
(0.014%)
⇧
(Oct. 16, 2026, 1:42 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 4:44 a.m. EDT
The immediate setup is a high-conviction momentum play driven by a massive gap-up event that has pushed the stock from a 25-dollar range to near 36 dollars. This surge has created a distinct 'floor' in the options chain, with traders aggressively buying protection at lower levels while betting on further appreciation via out-of-the-money calls. The statistical forecast model shows a negligible 0.05% directional lean, which is completely overshadowed by the fundamental catalyst of expanding reimbursement for their core drug, EXPAREL, and the resulting margin expansion. While the long-term valuation remains stretched with a trailing P/E of 103x, the company's fortress-like balance sheet—holding over $250 million in cash against manageable debt—and its ability to generate free cash flow provide a rare safety net for a biotech firm. The market appears to be pricing in a transition from a struggling generic manufacturer to a profitable specialty player, making this a compelling entry despite the lack of a dividend yield. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.131864 |
| AutoETS | 0.135642 |
| AutoARIMA | 0.136707 |
| MSTL | 0.137163 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 11.85 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.22 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 61.329 |
| Revenue per Share | 17.931 |
| Market Cap | 1,450,210,560 |
| Trailing P/E | 103.81 |
| Forward P/E | 10.50 |
| Beta | 0.25 |
| Profit Margins | 1.96% |
| Website | https://www.pacira.com |
As of Oct. 10, 2026, 4:44 a.m. EDT: Speculators are positioning for a significant upside move, evidenced by heavy out-of-the-money call open interest at strikes above the current price (37.5 and 40.0) expiring in early 2027. Conversely, put activity is concentrated deep in-the-money at lower strikes (15.0, 20.0), suggesting a floor rather than a bearish bet. The implied volatility is extremely low for long-dated calls, indicating complacency regarding a potential rally, while short-term IV remains elevated, reflecting recent price turbulence.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5885439 |
| Address1 | 2,000 Sierra Point Parkway |
| Address2 | Suite 900 |
| All Time High | 121.95 |
| All Time Low | 6.16 |
| Ask | 36.35 |
| Ask Size | 1 |
| Audit Risk | 1 |
| Average Analyst Rating | 2.8 - Hold |
| Average Daily Volume10 Day | 4,454,130 |
| Average Daily Volume3 Month | 1,198,054 |
| Average Volume | 1,198,054 |
| Average Volume10Days | 4,454,130 |
| Beta | 0.252 |
| Bid | 26.16 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 16.874 |
| City | Brisbane |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 36.335 |
| Current Ratio | 5.042 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 36.39 |
| Day Low | 36.33 |
| Debt To Equity | 61.329 |
| Display Name | Pacira BioSciences |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,875,400 |
| Earnings Call Timestamp Start | 1,785,875,400 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | 123,966,000 |
| Ebitda Margins | 0.16614 |
| Enterprise To Ebitda | 12.982 |
| Enterprise To Revenue | 2.157 |
| Enterprise Value | 1,609,268,352 |
| Eps Current Year | 2.89596 |
| Eps Forward | 3.45892 |
| Eps Trailing Twelve Months | 0.35 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 26.3562 |
| Fifty Day Average Change | 9.9788 |
| Fifty Day Average Change Percent | 0.378613 |
| Fifty Two Week Change Percent | 58.85439 |
| Fifty Two Week High | 36.67 |
| Fifty Two Week High Change | -0.33499908 |
| Fifty Two Week High Change Percent | -0.009135509 |
| Fifty Two Week Low | 18.8 |
| Fifty Two Week Low Change | 17.535 |
| Fifty Two Week Low Change Percent | 0.9327128 |
| Fifty Two Week Range | 18.8 - 36.67 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,296,743,400,000 |
| Float Shares | 39,130,420 |
| Forward Eps | 3.45892 |
| Forward P E | 10.504724 |
| Free Cashflow | 98,341,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 825 |
| Fullday Change | 0.0049972534 |
| Fullday Change Percent | 0.01375517 |
| Fullday Price | 36.335 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.79206 |
| Gross Profits | 591,009,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01338 |
| Held Percent Institutions | 1.0586799 |
| Implied Shares Outstanding | 39,912,226 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California. |
| Long Name | Pacira BioSciences, Inc. |
| Market | us_market |
| Market Cap | 1,450,210,560 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_27508 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 14,638,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 981,399,633 |
| Number Of Analyst Opinions | 7 |
| Open | 36.36 |
| Operating Cashflow | 187,663,008 |
| Operating Margins | 0.06165 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.99 |
| Phone | 650 242 8052 |
| Previous Close | 36.33 |
| Price Eps Current Year | 12.546788 |
| Price Hint | 2 |
| Price To Book | 2.1533127 |
| Price To Sales Trailing12 Months | 1.9435548 |
| Profit Margins | 0.01962 |
| Quick Ratio | 3.213 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.77778 |
| Region | US |
| Regular Market Change | 0.0049972534 |
| Regular Market Change Percent | 0.01375517 |
| Regular Market Day High | 36.39 |
| Regular Market Day Low | 36.33 |
| Regular Market Day Range | 36.33 - 36.39 |
| Regular Market Open | 36.36 |
| Regular Market Previous Close | 36.33 |
| Regular Market Price | 36.335 |
| Regular Market Time | 1,792,172,527 |
| Regular Market Volume | 239,354 |
| Return On Assets | 0.01476 |
| Return On Equity | 0.020480001 |
| Revenue Growth | 0.062 |
| Revenue Per Share | 17.931 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 39,912,226 |
| Shares Percent Shares Out | 0.2026 |
| Shares Short | 8,076,461 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 7,328,377 |
| Short Name | Pacira BioSciences, Inc. |
| Short Percent Of Float | 0.2912 |
| Short Ratio | 14.52 |
| Source Interval | 15 |
| State | CA |
| Symbol | PCRX |
| Target High Price | 36.5 |
| Target Low Price | 25.0 |
| Target Mean Price | 33.57143 |
| Target Median Price | 36.5 |
| Total Cash | 251,031,008 |
| Total Cash Per Share | 6.298 |
| Total Debt | 412,116,992 |
| Total Revenue | 746,163,968 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.35 |
| Trailing P E | 103.814285 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 24.1866 |
| Two Hundred Day Average Change | 12.148399 |
| Two Hundred Day Average Change Percent | 0.5022781 |
| Type Disp | Equity |
| Volume | 239,354 |
| Website | https://www.pacira.com |
| Zip | 94,005 |